Fertility and Pregnancy in Women with Transfusion-Dependent Thalassemia.

Because women with transfusion-dependent thalassemia are seeking pregnancy, ensuring the best outcomes for both mother and baby require concerted and collaborative efforts between the hematologist, obstetrician, cardiologist, hepatologist, and genetic counselor among others. Proactive counseling, early fertility evaluation, optimal management of iron overload and organ function, and application of advances in reproductive technology and prenatal screening are important in ensuring a healthy outcome. Many unanswered questions remain requiring further study, including fertility preservation, non-invasive prenatal diagnosis, chelation therapy during pregnancy, and indications and duration of anticoagulation.
Competing Interests: Disclosure FA Sayani: Grant/Research/Clinical Trial Support: Agios Pharmaceuticals, Celgene, Novartis, Imara, Protagonist. EP Vichinsky: Grant/Research/Clinical Trial Support: Agios Pharmaceuticals, Bluebird Bio, Global Blood Therapeutics, Novartis, Novo Nordisk. Consultant/Advisory Boards: BioMarin Pharmaceuticals, Bluebird bio, Chiesi Corp, Forma Therapeutics, Global Blood Therapeutics. All of the relevant financial relationships listed have been mitigated.
(Copyright © 2022 Elsevier Inc. All rights reserved.)